Company intelligence / Profile preview

Providence

Calgary, Alberta, Canadaprovidence.org ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Providence Therapeutics is a Canadian clinical-stage biotechnology company specializing in the development of mRNA therapeutics and vaccines. The company pivoted during the COVID pandemic to develop PTX-COVID19-B, an mRNA vaccine shown to be equivalent in efficacy to Pfizer/BioNTech's vaccine. It maintains a robust pipeline targeting both oncology and infectious diseases using its proprietary end-to-end mRNA-LNP platform.

Therapeutic areas: Infectious DiseasesOncology
Modalities: mRNA-based drugsLipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Described as having “exciting partnerships” post-pandemic with industry players for co-development opportunities but no specific partners named publicly.

Beyond the preview

Go deeper on Providence.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Providence.

Explore the full profile